Image Guided Radiotherapy Market Size

Image Guided Radiotherapy Market Size

Image Guided Radiotherapy Market size was valued at USD 1.9 billion in 2023 and is anticipated to witness growth at a CAGR of 7.3% between 2024 and 2032. The image-guided radiotherapy market is experiencing growth driven by the increasing incidence of cancer, a surging preference for personalized treatment planning, and a rise in the adoption of non-invasive cancer treatment.

The global incidence of cancer continues to rise, driven by factors such as population growth, aging demographics, lifestyle changes, and environmental factors. Cancer remains a significant public health concern worldwide, with millions of new cases diagnosed each year. For instance, according to the American Cancer Society, in 2022, approximately 20 million new cancer cases were diagnosed, resulting in 9.7 million deaths worldwide. With the increasing number of cancer patients, there is a growing demand for advanced treatment modalities like image-guided radiotherapy, which can effectively target and treat tumors while minimizing damage to surrounding healthy tissues.
 

Furthermore, non-invasive cancer treatments like image-guided radiotherapy (IGRT) are associated with fewer treatment-related side effects compared to invasive surgical procedures or systemic therapies such as chemotherapy. By delivering highly targeted radiation doses to cancerous tissues while sparing nearby healthy organs and tissues, IGRT minimizes the risk of radiation-induced toxicity and long-term complications. This not only improves patient tolerance to treatment but also enhances their overall treatment experience, leading to greater patient satisfaction and compliance.
 

Image-guided radiotherapy is a highly advanced form of radiation therapy that utilizes real-time imaging techniques to precisely target and deliver therapeutic radiation to tumors while minimizing exposure to surrounding healthy tissues. It integrates various imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) to visualize tumors and adjacent anatomy with high accuracy during both treatment planning and delivery.